DOCSLIB.ORG

Vaginitis Updates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaginitis Updates VAGINITIS UPDATE & TREATMENT PEARLS SANDY SULIK MD MEDICAL DIRECTOR PRIMARY CARE SERVICES – ST JOSEPH’S HEALTH ST JOSEPH’S FAMILY MEDICINE RESIDENCY PROFESSOR, UPSTATE MEDICAL CENTER I HAVE NO DISCLOSURES OBJECTIVES • Review the most common causes of vaginitis and treatments for each • Discuss emerging causes of vaginitis including mycoplasma genitalium and desquamative vaginitis • Discuss treatment strategies for recurrent vaginal infections VAGINITIS • One of the most frequent reasons to visit the OB/GYN office, Family Planning services, student health and primary care offices • ACCOUNTS FOR UP TO 10 MILLION OFFICE VISITS PER YEAR • Many women never get a clear diagnosis and often have recurrent symptoms • Causes discomfort and pain, days lost from work/school, discomfort with sexual functioning and issues with self image • Often associated with other STI’s, HIV, and other infections of the female genital tract VAGINITIS • Defined as a spectrum of conditions that cause vulvovaginal symptoms: • Itching • Burning • Irritation • Abnormal Discharge • Odor • Redness • Swelling • 3 Most Common etiologies of vaginitis: Trichomonas, Bacterial vaginosis, vulvovaginal candidiasis VAGINITIS – CLINICAL PRESENTATION • Inflammatory • presence of poly-morphonuclear neutrophils (PMNS) on microscopy • with physical findings of erythema and edema • Trichomonas, candidiasis, atrophic vaginitis, Mucosal erosive diseases, desquamative inflammatory vaginitis • Non-inflammatory • absence of PMNS • no erythema, no swelling with vaginal complaints of odor or abnormal discharge • Bacterial vaginosis most common, mixed VVC/BV BACTERIAL VAGINOSIS • Vulvovaginal infection caused by a pathogenic shift of the vaginal flora with a polymicrobial overgrowth of facultative and anaerobic organisms • Most common cause of vaginal complaints • Most common in women of reproductive age • More prevalent in African-American and/or American-Hispanic women than white women • Even adjusting for age, education, poverty – 3 x more common • Other risk factors: douching, recent course of antibiotic therapy, hypoestrogenism, smoking, IUD use • Decreased risk with estrogen-containing contraceptives and consistent condom use IMPLICATIONS OF BV INFECTION • Associated with obstetrical complications: • Preterm labor, PPROM, low birth weight, post partum endometritis, spontaneous abortion • Associated with surgical complications • Post-abortal endometritis, vaginal cuff cellulitis or abscess after hysterectomy, PID • Increased risk of acquiring other infections • HIV, HSV2, Neisseria gonorrhea, Chlamydia trachomatis, Trichomonas vaginalis, UTI’s SEXUAL TRANSMISSION? • Has been implicated in recurrent BV • Epidemiological studies are mixed • Multiple studies show up to 60% increased risk for BV in women with multiple sexual partners • Protective effect from both incident and recurrent BV with condom use SYMPTOMS AND FINDINGS • Typical presentation includes foul smelling or fishy vaginal discharge • Complaint of malodor is highly associated with BV (LR 3.2 [95% CI 2.1-4.7]) • Lack of perceived odor makes BV unlikely LR 0.07 (95% CI 0.01-0.51) • May be exacerbated by conditions that elevate the vaginal pH • Sexual intercourse with semen deposition • Presence of blood • Itching and burning unlikely (if present consider mixed infection with yeast or other inflammatory process), doesn’t usually cause dyspareunia • Examination findings: thin gray-white discharge, should not see erythema, fissuring or bleeding DIAGNOSTIC TESTING • Clinical diagnosis made by microscopic examination and measurement of vaginal pH • Classically 3 of 4 of Amsel’s criteria must be met • Thin homogenous gray-white discharge • An increased pH >4.5 • Release of an amine odor upon application of potassium hydroxide (+ Whiff test) • >20% clue cells on saline microscopy LAB TESTING • Saline wet mount • A wet smear that shows more than 20% of the epithelial cells are clue cells COMMERCIAL TESTS/NAAT AFFIRM VP III OSOM BVBLUE DNA probe testing that identifies Chromogenic test based on sialidase produced by Gardnerella vs Trichomonas and Candida Gardnerella, Bacteroides, etc on DNA concentrations Sensitivity 90% Specificity is 68% Sensitivity 88-98% and Specificity 95-97% compared to Gram stain TREATMENT OF BV • First line: 7 day course of oral metronidazole 500 mg BID • 7 day course of intravaginal clindamycin cream or 5 day course of intravaginal metronidazole gel • Clindamycin 300 mg orally for 7 days • Secnidazole (Secondax®/Solosec®) approved in 2018 for treatment of incident BV • Has a longer half life than metronidazole • Single dose regimen of 2 Gm • Intravaginal Clindamycin ovules x 3 days • Tinidazole 1 Gm daily for 5 days or 2 gm daily for 2 days • ALL regimens equally effective may respond to a second course of same therapy if first ineffective RECURRENT BV • Greater than 50% of women will have a repeat episode of BV within 1 year of treatment • Recurrent BV defined as 3 or more symptomatic episodes within 1 year • Failure of symptom resolution during appropriate antibiotic treatment should raise suspicion for mixed infection and need for further evaluation • Risk factors: prior history of BV, having a regular sex partner, having female sex partner, presence of both G vaginalis and A vaginae • Mechanisms: reinfection by sexual activity, failure to re-establish normal lactobacillus predominant flora, formation of biofilms TREATMENT OF RECURRENT BV • CDC recommendations 3 options after completion of a standard regimen: • Metronidazole vaginal gel 0.75% one full applicator twice weekly for 6 months • With the initiation of a standard treatment regimen start a 21 day course of vaginal boric acid capsules 600 mg once daily at bedtime. At completion of the boric acid treatment, start metronidazole vaginal gel 0.75% twice weekly for 6 months • After completion of standard regimen start oral metronidazole 2g and fluconazole 150 mg once every month RECURRENT BV TREATMENT • Other regimens that have been used: • Intravaginal metronidazole daily for 10 days followed by twice weekly for 4-6 months • Oral or intravaginal metronidazole for 3 days at the onset of menses for 3-6 months with antifungal therapy if history of candidiasis • In Canada a vaginal ovule with metronidazole 500 mg with nystatin 10,000 IU is available and can be used monthly to prevent recurrence TREATMENT OF PARTNERS • Not recommended • Studies to date are flawed and inconclusive • For women who have sex with women the rate of BV concordance among partners is high • If partner is symptomatic – reasonable to treat both • Small studies have shown male circumcision may reduce the risk of BV in female partners OTHER TREATMENTS • Vaginal administration of lactic acid to help restore the acidic pH of the vagina is thought to be helpful • Number of products available: Luvena, Gynofit gel • Oral Lactobacillus to improve the vaginal microbiome • Number of small studies have inconclusive evidence for or against Probiotics in treatment of BV USE OF POLICARBOPHIL-CARBOPOL ACIDIC VAGINAL GEL • A persistent high vaginal pH(>4.7) is a common alteration in women with recurrent BV • Use of a polycarbophil has been shown to be effective in reducing the vaginal pH • Polycarbophil is a weak polyacid large molecule that is neither absorbed nor immunogenic • It adheres to the vaginal epithelial cells until they turn over (3-5 days), buffers vaginal secretions near physiologic ph (4.3) POLICARBOPHIL-CARBOPOL ACIDIC GEL • Several small studies have shown use has effectively treated recurrent BV • No RCT’s have been done to date • One study used daily treatment of 2.5g of gel for one week followed by twice weekly for 6 weeks • 2nd study used 2.5 g biweekly for 6 weeks • Both showed improvement in BV and decreased recurrence compared to placbo or acidic douche USE OF VITAMIN C VAGINAL TABLETS • Several small studies have shown efficacy with Vitamin C Vaginal tablets • 250 mg silicon-coated vaginal tablets daily for 6 days • Studies showed statistically significant improvement in BV in the Vitamin C treated groups IUDS AND BV • The relationship between IUD use and BV is unclear – insufficient evidence to conclude one way or other • Thought to be related to the increase of unscheduled bleeding leading to a higher vaginal pH EFFECT OF DIET AND BV • One study looked at diet and occurrence of BV • Increased dietary fat (saturated fats) was associated with an increase in BV and severe BV • Significant inverse association of BV with diets high in folate, calcium and Vitamin E TRICHOMONAS • Trichomonas vaginalis: flagellated motile anaerobic protozoan organism which colonizes the vagina, urethra, par-urethral and Skene glands • Transmission is primarily sexual, can transmit via fomites, hot tubs, pools • Affects 3.7 million persons in the US annually • Prevalence in women 40 years and older is 11% overall and more common in women diagnosed with other STI’s including HIV • African-American women are disproportionally affected with a prevalence of 15% compared with 1.8% of white women IMPLICATIONS • Obstetric • Preterm birth, PROM, low birth weight • Gynecologic • Often coexists with other STI’s, HPV, and BV • PID and tubal infertility • Endometritis after delivery, abortion, or surgery • Facilitates acquisition and transmission of HIV RISK FACTORS • Change in sexual partners • Frequent sexual intercourse • Having 3 or more sexual partners in a month • Coexistent sexually transmitted infections (HIV) • Illicit drug use, smoking • Lack of barrier contraception • Low socio-economic
Load more

Recommended publications
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • Dysmenorrhoea
    [ Color index: Important | Notes| Extra | Video Case ] ​ ​ ​ ​ ​ ​ ​ ​ Editing file link ​ Dysmenorrhoea Objectives: ➢ Define dysmenorrhea and distinguish primary from secondary dysmenorrhea ➢ • Describe the pathophysiology and identify the etiology ➢ • Discuss the steps in the evaluation and management options References : Hacker and moore, Kaplan 2018, 428 boklet ,433 , video case ​ Done by: Omar Alqahtani ​ Revised by: Khaled Al Jedia ​ DYSMENORRHEA Definition: dysmenorrhea is a painful menstruation it could be primary or secondary ​ ​ Primary dysmenorrhea Definition: Primary dysmenorrhea refers to recurrent, crampy lower abdominal pain, along ​ ​ with nausea, vomiting, and diarrhea, that occurs during menstruation in the absence of pelvic pathology. It is the most common gynecologic complaint among adolescent girls. ​ ​ Characteristic: ​ The onset of pain generally does not occur until ovulatory menstrual cycles are established. ​ ​ Maturation of the hypothalamic-pituitary-gonadal axis leading to ovulation occurs in half of the teenagers within 2 years post-menarche, and the majority of the remainder by 5 years post-menarche. (so mostly it’s occur 2-5 years after first menstrual period) ​ • The symptoms typically begin several hours prior to the onset of menstruation and continue ​ ​ for 1 to 3 days. ​ ​ • The severity of the disorder can be categorized by a grading system based on the degree of menstrual pain, the presence of systemic symptoms, and impact on daily activities Pathophysiology Symptoms appear to be caused by excess production of endometrial prostaglandin F2α ​ ​ resulting from the spiral arteriolar constriction and necrosis that follow progesterone withdrawal as the corpus luteum involutes. The prostaglandins cause dysrhythmic uterine contractions, hypercontractility, and increased uterine muscle tone, leading to uterine ischemia.
    [Show full text]
  • Infertility Diagnosis and Treatment
    UnitedHealthcare® Oxford Clinical Policy Infertility Diagnosis and Treatment Policy Number: INFERTILITY 008.12 T2 Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Follicle Stimulating Hormone (FSH) Gonadotropins Documentation Requirements ...................................................... 2 • Human Menopausal Gonadotropins (hMG) Definitions ...................................................................................... 3 • Preimplantation Genetic Testing Prior Authorization Requirements ................................................ 3 Applicable Codes .......................................................................... 3 Related Optum Clinical Guideline Description of Services ................................................................. 3 • Fertility Solutions Medical Necessity Clinical Benefit Considerations .................................................................. 7 Guideline: Infertility Clinical Evidence ........................................................................... 8 U.S. Food and Drug Administration ........................................... 14 References ................................................................................... 15 Policy History/Revision Information ........................................... 18 Instructions for Use ..................................................................... 18 Coverage Rationale See Benefit Considerations
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • 209627Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Vaginal Delivery System
    (19) & (11) EP 2 062 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 9/00 (2006.01) (21) Application number: 07397042.8 (22) Date of filing: 22.11.2007 (84) Designated Contracting States: • Hanes, Vladimir AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tarrytown, NY 10591 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Keinänen, Antti SI SK TR 20540 Turku (FI) Designated Extension States: • Holmberg, Svante AL BA HR MK RS 20900 Turku (FI) • Nikander, Hannu (71) Applicant: Bayer Schering Pharma Oy 21330 Paattinen (FI) 20210 Turku (FI) (74) Representative: Matilainen, Mirja Helena et al (72) Inventors: Oy Jalo Ant-Wuorinen AB, • Talling, Christine Iso Roobertinkatu 4-6 A 20610 Turku (FI) 00120 Helsinki (FI) (54) Vaginal delivery system (57) The present invention is related to an intravag- brane (3) encasing the core, said core and membrane inal delivery system for the controlled release of a pro- essentially consisting of a same or different polymer com- gestogen and an estrogen, comprising additionally a position, wherein at cast one of the cores comprises a therapeutically active or a health-promoting substance progestogen or a mixture of a progestogen and an es- (1) capable of giving and/or enhancing the protection trogen, and another core may comprise an estrogen or against bacterial and fungal infections, and/or enhancing a progestogen, and wherein the membrane or the surface the protection against sexually transmitted diseases. The of the membrane or at least one of the cores comprises delivery system consists of one or more compartments said therapeutically active or a health-promoting sub- (2,4,5), one of each comprising a core (7) and a mem- stance.
    [Show full text]
  • Recurrent Miscarriage
    Elizabeth Taylor, MD, FRCSC, Mohammed Bedaiwy, MD, PhD, Mahmoud Iwes, MD Recurrent miscarriage Management of pregnancy loss includes investigating causes, addressing modifiable risk factors, and providing supportive care in the first trimester of pregnancy. ABSTRACT: Early miscarriages are arly miscarriage has been re­ Genetic causes those occurring within the first 12 ported to occur in 17% to 31% The risk of miscarriage increases completed weeks of gestation. Re- E of pregnancies,1,2 and is de­ with maternal age. At age 20 to 24 current miscarriage, defined as two fined as a nonviable intrauterine the risk is approximately 10%, with or more consecutive pregnancy loss- pregnancy with either an empty ges­ risk increasing to nearly 80% by age es, affects 3% of couples trying to tational sac or a gestational sac con­ 45.5 The relationship between mis­ conceive and can cause consider- taining an embryo or fetus without carriage risk and maternal age can be able distress. The risk of miscarriage fetal heart activity within the first explained by the increasing rate of oo­ increases with maternal age. Genet- 12 completed weeks of gestation.3 cyte aneuploidy that occurs as women ic abnormalities, uterine anomalies, Recurrent miscarriage occurs in 3% grow older. In one study, oocytes and endocrine dysfunction can all of couples trying to conceive. The examined during in vitro fertilization lead to miscarriage. Other causes of American Society for Reproductive (IVF) treatment had only a 10% risk miscarriage are autoimmune disor- Medicine (ASRM) defines recurrent of being aneuploid in women younger ders such as antiphospholipid syn- miscarriage as two or more failed than age 35, but by age 43 the risk of drome and chronic endometritis.
    [Show full text]
  • Male Infertility and Risk of Nonmalignant Chronic Diseases: a Systematic Review of the Epidemiological Evidence
    282 Male Infertility and Risk of Nonmalignant Chronic Diseases: A Systematic Review of the Epidemiological Evidence Clara Helene Glazer, MD1 Jens Peter Bonde, MD, DMSc, PhD1 Michael L. Eisenberg, MD2 Aleksander Giwercman, MD, DMSc, PhD3 Katia Keglberg Hærvig, MSc1 Susie Rimborg4 Ditte Vassard, MSc5 Anja Pinborg, MD, DMSc, PhD6 Lone Schmidt, MD, DMSc, PhD5 Elvira Vaclavik Bräuner, PhD1,7 1 Department of Occupational and Environmental Medicine, Address for correspondence Clara Helene Glazer, MD, Department of Bispebjerg University Hospital, Copenhagen NV, Denmark Occupational and Environmental Medicine, Bispebjerg University 2 Departments of Urology and Obstetrics/Gynecology, Stanford Hospital, Copenhagen NV, Denmark University School of Medicine, Stanford, California (e-mail: [email protected]). 3 Department of Translational Medicine, Molecular Reproductive Medicine, Lund University, Lund, Sweden 4 Faculty Library of Natural and Health Sciences, University of Copenhagen, Copenhagen K, Denmark 5 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 6 Department of Obstetrics/Gynaecology, Copenhagen University Hospital, Hvidovre, Denmark 7 Mental Health Center Ballerup, Ballerup, Denmark Semin Reprod Med 2017;35:282–290 Abstract The association between male infertility and increased risk of certain cancers is well studied. Less is known about the long-term risk of nonmalignant diseases in men with decreased fertility. A systemic literature review was performed on the epidemiologic evidence of male infertility as a precursor for increased risk of diabetes, cardiovascular diseases, and all-cause mortality. PubMed and Embase were searched from January 1, 1980, to September 1, 2016, to identify epidemiological studies reporting associations between male infertility and the outcomes of interest. Animal studies, case reports, reviews, studies not providing an accurate reference group, and studies including Downloaded by: Stanford University.
    [Show full text]
  • NPTC-Formulary Brief Acne
    Indian Health Service National Pharmacy and Therapeutics Committee Formulary Brief: Treatment of Acne vulgaris -January 2020- Background: The Indian Health Service (IHS) National Pharmacy and Therapeutics Committee (NPTC) reviewed the medical management of acne vulgaris at their January 2020 meeting. This review included topical therapies (retinoids, antibiotics, bactericidal and other anti-comedonal or anti-inflammatory agents) and oral therapies (antibiotics, isotretinoin, oral contraceptives, antiandrogens). Topical clindamycin, topical tretinoin, spironolactone, and combined estrogen-containing oral contraceptives are currently on the IHS National Core Formulary (NCF). Following clinical review, pharmacoeconomic evaluation and internal deliberation, the NPTC voted to ADD (1.) benzoyl peroxide (any topical formulation) and REPLACE topical clindamycin with (2.) combination clindamycin and benzoyl peroxide gel to the NCF. Discussion: Acne is the most common skin disorder in the United States (US), affecting 40-50 million persons of all ages. It can have significant sequelae from physical scarring, persistent hyperpigmentation, and psychological issues. Small studies focused on acne among American Indian/Alaska Native (AI/AN) populations suggest that the prevalence of acne is similar to other racial/ethnic groups in the US, but that the sequelae of scarring is significantly higher (55% in AI/AN vs. 3% among US white populations) and access to specialty care services is disproportionately low1. Acne is a chronic inflammatory disease of the pilosebaceous unit involving increased sebum production by sebaceous glands, hyperkeratinization of the follicle, colonization of the follicle by Propionobacterium acnes, and an inflammatory reaction. Acne is manifested with both non-inflammatory (open and closed comedones) and inflammatory lesions (papules, pustules, and nodules). Inflammatory acne is graded as mild, moderate, or severe based on the frequency of the various inflammatory lesions.
    [Show full text]
  • Emerging Threat in Antifungal Resistance on Superficial Dermatophyte Infection R Sultana1, M Wahiduzzaman2
    Bang Med J Khulna 2018; 51 : 21-24 ORIGINAL ARTICLE Emerging threat in antifungal resistance on superficial dermatophyte infection R Sultana1, M Wahiduzzaman2 Abstract Background: Dermatophytosis are most common fungul infection globally and according to WHO the prevalence is about 20-25% and does not spare people of any race or age. Over the past few years antifungal resistance has been emerged due to irrational use of antifungal drugs in cutaneous mycosis. Objective: The aim of the study is to evaluate the efficacy of different antifungul drugs (Terbinafin. Fluconazole, Itraconazole, Griseofulvin) on superficial mycosis depending on various factors. Methods: This prospective study was conducted among the Superficial fungul infected patients from April' 2017 to October 2017 in Khulna Medical College Hospital (KMCH) and dermatologist's private chamber in Khulna city. All the enrolled patients were put on oral Terbinafin, Fluconazole, Itraconazole and Griseofulvin. Each patient was given single antifungal drug orally. These cases were thus followed up after two months of treatment to look for persistent infection, cure or any relapse clinically. Result: Among 194 patient 89 were given Tab. Terbinafin (250mg) where resistance cases were 20.22%. More cases (33.96%) were resistant to Cap. Fluconazol (50mg). High percentage of cases were resistant to Cap. Itraconazole (76.47%). Griseofulvin resistant cases were observed in 25.71%. Drug response is very poor (69%) in patient who had been suffering from diabetes mellitus. Conclusion: Appropriate antifungal drugs should be chosen with strict indication, dose, duration, selection of perfect local preparation and taking laboratory facilities where necessary. Keywords : Dermatophytosis, Antifungal resistance, Public health.
    [Show full text]
  • Vaginitis No Disclosures Related to This Topic
    Vaginitis No disclosures related to this topic Is the wet prep out of the building? Images are cited with permissions Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health Center Michigan Medicine Ann Arbor, Michigan Women with vaginal discharge Is vaginal discharge ever “normal ”? Normal 30% Bacterial vaginosis 23-50% Few primary studies and most of low quality. Candida vaginitis 20-25% Quantity and quality of vaginal discharge varies considerably across women and during the Mixed 20% menstrual cycle. Desquamative inflammatory 8% Symptom of vaginal discharge is non-specific. Vaginitis Vaginal discharge is often thought to be vaginitis. Trichomoniasis 5-15% Vaginal symptoms are very common Patient with chronic vaginal discharge Presence or absence of a microbe corresponds poorly with the presence or absence of 17 year old GO complains of lots of heavy white symptoms. vaginal discharge which is bothersome. No agreement about timing, color or Regular periods, denies any sexual activity. characteristics of discharge among women with Numerous evaluations for STI’s, all negative. vaginal discharge Treated for vaginal candida, BV and trich Most women think vagina should be “dry ”. although there was no evidence for any Vaginal wetness may be normal . infection and did not resolve discharge. Schaaf et al. Arch Intern Med 1999;150. Physiologic vaginal discharge 17 year old Chronic vaginal Patients and providers may consider that a thick discharge white discharge is most frequently caused by candidiasis. Always wears a pad May lead to repeated use of unnecessary antifungal therapy and prompt concerns of Diagnosis? recurrent infection if not resolved.
    [Show full text]